EU–Singapore arrangement opens a new channel for medicines and device information sharing

What was agreed

On 11 November 2026, the European Commission's DG SANTE announced a working arrangement with Singapore on cooperation in medicines and medical devices. DG SANTE and the EMA have agreed with Singapore's Health Sciences Authority (HSA) to exchange information on both product categories, and the arrangement takes effect immediately.

That is all the published record says. It names the parties, the two product areas and the start date. It does not say what kinds of information will be shared, how often, through which contacts, or under what confidentiality terms.

What is not yet known

For pharmacovigilance professionals, the open questions matter more than the headline. The record does not say whether the exchange covers safety signals, inspection findings, benefit-risk assessments, device vigilance reports or recall information. It also does not say whether information flows in both directions in real time or on request, or whether any mechanism for joint work is planned.

Until the Commission or EMA publishes the text or a fuller description, it would be a mistake to assume the arrangement changes anything for marketing authorisation holders. Working arrangements of this kind are generally administrative agreements between authorities. They do not by themselves alter the legal reporting obligations companies already have in the EU or in Singapore.

Why the timing is instructive

The same week's regulatory output shows how safety information appears in different places and at different speeds. On 10 November, EMA's safety committee PRAC began a referral on flupentixol/melitracen (Deanxit) over serious neurological and psychiatric effects. It also started a signal assessment of allergic reactions to human normal immunoglobulins, linked to specific batches. The day before, the FDA required a Warnings and Precautions entry on a potential increased risk of non-arteritic anterior ischaemic optic neuropathy (NAION) on all GLP-1 receptor agonist labels.

On the device side, the FDA published early alerts on Intersurgical's 22mm Smoothbore breathing systems (connector detachment risk) and on Arrow International's hydrophilic-coated spring wire guide products (coating detachment). Health Canada listed a Type I recall of Merit Medical's Surfacer Inside-Out access catheter system sheath and dilator after four complaints, two involving adverse events. The Dutch inspectorate IGJ published a field safety notice from FIM Medical on its Audiolyser ADL Connect audiometer after two reports of a louder 250 Hz tone than selected.

None of these records mention Singapore, and nothing in them suggests the products or signals are connected to the new arrangement. The point is structural. Each regulator publishes through its own channel on its own timetable, and a single issue can surface in one jurisdiction days or weeks before another. Formal information exchange is one way authorities narrow that gap.

Regulatory context

The EU already works with many non-EU regulators, and the EMA is increasingly open about its efforts to modernise how the network operates. A new EMA page published the same day sets out how AI is moving from concept to practice in medicine regulation, with expected outcomes across the EU network and a timeline of milestones from 2021 to August 2026. The records do not link that page to the Singapore arrangement, and nothing indicates AI features in it.

Still, the two items point the same way: regulators are investing in how they handle and share information. For QPPVs, the practical effect is that a safety decision or device action in one region is more likely to be known to another authority, and sooner, than may have been the case in the past. That is an inference about direction of travel, not something the records state.

Who is affected and what to watch

Directly affected are the authorities themselves. Indirectly, any company with products authorised or marketed in both the EU and Singapore, whether medicines or devices, should assume that regulators may compare notes. That applies particularly where a safety variation, a recall or an inspection outcome in one market could be of interest in the other.

Watch for three things. First, whether the Commission or the EMA publishes the arrangement's text or a Q&A covering scope and confidentiality. Second, whether the HSA issues its own communication that clarifies how it will use information received. Third, whether future PRAC outputs or device safety communications reference cooperation with Singapore. Until then, the arrangement is a signal of intent rather than a change in obligations.